Fungal Disease Studies

Fungi are everywhere. Most fungi are not dangerous, but some types can be harmful to health, and people with deficient immune systems are more vulnerable to symptomatic infection. NIAID researchers are exploring how fungal susceptibility and infection impact the function of immune cells.

Current Clinical Research Studies Seeking Volunteers

The following are selected clinical trials supported by NIAID and investigating various aspects of fungal disease. The links lead to full study descriptions, eligibility criteria and contact information.

NCT02663674: Early Fluconazole Treatment for Coccidiodomycosis Pneumonia

This is a Phase IV randomized, double-blinded, placebo-controlled study in 1,000 individuals aged 18 years and older, with community acquired pneumonia who meet all eligibility criteria in endemic regions. This study is designed to provide data on the effectiveness of early antifungal treatment (Fluconazole) for coccidiodiomycosis pneumonia (also referred to as Valley Fever) vs. placebo.

14-I-0146: Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis

Researchers want to study the immune systems of people with disseminated coccidioidomycosis (DCM) or refractory coccidioidomycosis (RCM) to learn more about the disease and the best ways to treat it. People over the age of 2 years with DCM or RCM may be eligible to participate.

16-I-0002: CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis (CAMB)

This study seeks to determine the efficacy, safety, and pharmacokinetics of a novel oral formulation of the antifungal amphotericin. People ages 18 to 75 years with chronic mucocutaneous candidiasis who are not responding to standard non-intravenous treatment may be eligible to participate.

13-I-0181: Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women

Antibiotics increase the risk for yeast infections, but it is unclear why. The objective of this study is to see how a common antibiotic changes healthy bacteria in the vagina, and how these changes may increase the risk for yeast infections. Healthy women ages 18 to 40 years who are not allergic to penicillin may be eligible to participate.

99-I-0084: New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia

This study is designed to collect respiratory secretion specimens and blood samples to facilitate studies of human pneumocystis infection and disease, to detect genes associated with drug resistance, and to assess strain variation. People ages 3 to 99 years who are immunosuppressed with acute pneumonia and their families may be eligible to participate.

13-I-0082: Rituximab for Anti-cytokine Autoantibody-Associated Disease

Anti-cytokine autoantibody-associated diseases can cause severe illnesses and are difficult to treat with standard drugs. This study seeks people with anti-cytokine autoantibody-associated diseases what are at least 18 years old to see if rituximab is a safe and effective treatment.

09-I-0102: Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

The primary objective of this study is to further characterize the natural history of idiopathic CD4 lymphocytopenia (ICL) while also investigating the genetic, environmental, and immunologic features of the condition. ICL patients ages 18 years and up may be eligible to participate along with their relatives and household contacts.

10-I-0216: Studies of Disorders With Increased Susceptibility to Fungal Infections

The objective of this study is to collect blood and other biological samples to study immune disorders that make individuals more susceptible to fungal infections. Patients with abnormalities of immune function as manifested by recurrent or unusual fungal infections, recurrent or chronic inflammation, or previous laboratory evidence of immune dysfunction are eligible for screening and assessment under this protocol.

NCT01869829: Pediatric Antifungal Comparative Effectiveness (PEACE)

This is a multicenter, national and international, prospective observational comparative effectiveness study. The overarching objective is to develop new evidence-based treatment guidelines for invasive fungal diseases in children. People ages 120 days to 18 years with documented, proven, or probable case of invasive candidiasis may be eligible to participate.

93-I-0106: Evaluation and Follow-up of Patients With Cryptococcosis

This 5-year study follows the course of disease in previously healthy patients with cryptococcosis who developed the disease for no identifiable reason. Individuals with a positive culture of Cryptococcus neoformans who are 18 years of age and older without HIV infection or other condition predisposing to cryptococcosis (such as high-dose corticosteroid therapy, sarcoidosis, or a blood cancer) may be eligible to participate.

11-I-0187: Natural History of Individuals With Immune System Problems That Lead to Fungal Infections

This study collects medical information and samples for a long-term study of people with immune system problems that lead to fungal infections. People with a history of fungal infections caused by immune system problems and their family members may be eligible to participate.

Content last reviewed on August 14, 2017